-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 VbjTqwLudjXpDQzwtE63XtZRUlbkRS10JgAaDCp313PllU9Kx5SxMwXUVreh+Gne
 dahMrSgzs7k+ku8WSj3vnQ==

<SEC-DOCUMENT>0000950124-05-002684.txt : 20050426
<SEC-HEADER>0000950124-05-002684.hdr.sgml : 20050426
<ACCEPTANCE-DATETIME>20050426073028
ACCESSION NUMBER:		0000950124-05-002684
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20050426
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20050426
DATE AS OF CHANGE:		20050426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TARGETED GENETICS CORP /WA/
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23930
		FILM NUMBER:		05771508

	BUSINESS ADDRESS:	
		STREET 1:		1100 OLIVE WAY
		STREET 2:		STE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
		BUSINESS PHONE:		2066237612

	MAIL ADDRESS:	
		STREET 1:		1100 OLIVE WAY
		STREET 2:		STE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v08321e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>






<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>


<P align="center" style="font-size: 10pt"><B>___________</B>


<P align="center" style="font-size: 18pt"><B>FORM 8-K<BR>
CURRENT REPORT</B>


<P align="center" style="font-size: 10pt"><B>Pursuant To Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B>


<P align="left" style="font-size: 10pt">Date of Report (Date of earliest event reported) <U> <B>April&nbsp;26, 2005</B></U>


<P align="center" style="font-size: 24pt"><B>Targeted Genetics Corporation</B>



<DIV align="left" style="font-size: 10pt"><HR size="1" noshade width="100%" align="center" color="#000000"></DIV>


<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Washington</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>0-23930</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>91-1549568</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction<BR>
of incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File<BR>
Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>1100 Olive Way, Suite&nbsp;100, Seattle, Washington</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>98101</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="left" style="font-size: 10pt">Registrant&#146;s telephone number, including area code <U> <B>(206)&nbsp;623-7612</B></U>



<P align="center" style="font-size: 10pt"><B>Not Applicable</B>



<DIV align="left" style="font-size: 10pt"><HR size="1" noshade width="100%" align="center" color="#000000"></DIV>


<DIV align="center" style="font-size: 10pt">(Former name or former address if changed since last report)</DIV>


<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;&nbsp;&nbsp;</TD>
    <TD><FONT style="font-family: Wingdings">&#168;</FONT> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;&nbsp;&nbsp;</TD>
    <TD><FONT style="font-family: Wingdings">&#168;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;&nbsp;&nbsp;</TD>
    <TD><FONT style="font-family: Wingdings">&#168;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;&nbsp;&nbsp;</TD>
    <TD><FONT style="font-family: Wingdings">&#168;</FONT> Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR>

</TABLE>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt"><B>Item&nbsp;2.02. </B><U><B>Results And Operations Of Financial Condition</B></U><B>.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On April&nbsp;26, 2005, Targeted Genetics Corporation, or the Registrant, issued a press release
announcing its financial results for the quarter ended March&nbsp;31, 2005. A copy of this press release
is furnished as Exhibit&nbsp;99.1 to this Current Report on Form 8-K.
The information in this report is being furnished pursuant to Item&nbsp;2.02 of Form 8-K, insofar as it
discloses historical information regarding the Registrant&#146;s results of operations and financial
condition as of, and for the quarter ended March&nbsp;31, 2005. In accordance with General Instructions
B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit&nbsp;99.1, shall
not be deemed &#147;filed&#148; for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such a filing.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01. </B><U><B>Financial Statements and Exhibits</B></U><B>.</B>


<P align="left" style="font-size: 10pt">Exhibits.


<P align="left" style="font-size: 10pt">As described above, Exhibit&nbsp;99.1 is furnished as part of this Current Report on Form 8-K:


<P align="left" style="font-size: 10pt">99.1 Press Release Dated April&nbsp;26, 2005.



<P align="center" style="font-size: 10pt">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><FONT style="font-variant: SMALL-CAPS">Targeted Genetics Corporation</FONT><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/Todd E. Simpson
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Todd E. Simpson&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Vice President, Finance and Administration and Chief
Financial Officer, Secretary and Treasurer<BR>
(Principal Financial and Accounting Officer)<BR>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Dated: April&nbsp;26, 2005



<P align="center" style="font-size: 10pt">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><U>EXHIBIT INDEX</U>



<P align="left" style="font-size: 10pt">99.1 Press Release Dated April&nbsp;26, 2005




<P align="center" style="font-size: 10pt">4
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v08321exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="right" style="font-size: 10pt"><B>Exhibit&nbsp;99.1</B>



<P align="center" style="font-size: 10pt"><IMG src="v08321v0832100.gif" alt="(TARGETED GENETICS LOGO)"> <B>&#174;</B>



<P align="left" style="font-size: 10pt"><B>Investor and Media Contact:</B><BR>
Stacie D. Byars<BR>
Director, Communications<BR>
Targeted Genetics<BR>
206.521.7392


<P align="center" style="font-size: 10pt"><B>TARGETED GENETICS REPORTS FIRST QUARTER 2005 FINANCIAL RESULTS</B>


<P align="left" style="font-size: 10pt"><B>Seattle, WA </B>&#150; April&nbsp;26, 2004 &#150; Targeted Genetics Corporation (NASDAQ: TGEN) today announced its
financial results for the first quarter of 2005. As previously announced, the Company will hold a
conference call with analysts at 10:00 AM EDT today. The call will be broadcast live and can be
accessed, along with replay information, at www.targetedgenetics.com.


<P align="left" style="font-size: 10pt">For the first quarter of 2005, the Company reported a net loss of $4.7&nbsp;million, or $0.05 per common
share, compared to a net loss of $4.9&nbsp;million, or $0.07 per common share, for the first quarter of
2004. Revenue for the first quarter of 2005 was $2.0&nbsp;million, compared to $1.3&nbsp;million for the
same quarter in the prior year. Revenue in 2005 and 2004 consists primarily of development revenue
earned under the HIV/AIDS vaccine collaboration with the International AIDS Vaccine Initiative
(IAVI).


<P align="left" style="font-size: 10pt">&#147;We are focused on advancing our clinical programs as well as leveraging value from our development
infrastructure, and we have made significant progress on both already this year,&#148; said H. Stewart
Parker, president and chief executive officer of Targeted Genetics. &#147;Specifically, we continue to
accrue patients in our Phase I inflammatory arthritis trial with the goal of providing data
mid-year. In our HIV/AIDS vaccine program, we released preliminary data of the ongoing Phase I
trial in Europe demonstrating a well-tolerated safety profile and have extended this study to
include India. Pending regulatory approvals, we plan to further expand this trial to evaluate the
safety and immunogenicity of the vaccine after a second dose. We also completed our Phase II study
in cystic fibrosis, however were disappointed the data revealed that we did not meet the primary
endpoint and have discontinued the program. Finally, we entered into two important collaborations,
adding preclinical programs to our pipeline in congestive heart failure and Huntington&#146;s disease,
and are now moving these robust development programs forward.&#148;


<P align="left" style="font-size: 10pt">Operating expenses were $6.6&nbsp;million for the first quarter of 2005, compared to $6.2&nbsp;million the
first quarter of 2004. Research and development expenses increased to $4.5&nbsp;million for the three
months ended March&nbsp;31, 2005, from $4.2&nbsp;million for the same period of 2004. General and
administrative

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt">expenses for the first quarter of 2005 were $1.9&nbsp;million, compared to $1.8&nbsp;million for the same
period in 2004.


<P align="left" style="font-size: 10pt">&#147;After adjustments were made due to the discontinuation of the cystic fibrosis program, and
including funding from the new collaborations this quarter, we reduced our operating cash
requirements for 2005 by approximately $2.5&nbsp;million, or to a range of $20 to $22&nbsp;million,&#148; said
Todd Simpson, Vice President Finance and Administration, Chief Financial Officer.


<P align="left" style="font-size: 10pt">First quarter highlights include:



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&#149;&nbsp;&nbsp;</TD>
    <TD>Reported preliminary results from Phase I trial of HIV/AIDS vaccine program &#150;no safety
concerns were identified and the vaccine was well tolerated;</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&#149;&nbsp;&nbsp;</TD>
    <TD>Extended Phase I clinical program of HIV/AIDS vaccine into India that is also underway
in Belgium and Germany;</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&#149;&nbsp;&nbsp;</TD>
    <TD>Expanded AAV-based gene delivery platform into the area of RNA interference through
collaboration with Sirna Therapeutics to develop treatment for Huntington&#146;s disease;</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&#149;&nbsp;&nbsp;</TD>
    <TD>Established collaboration with Celladon Corporation to develop AAV-based gene therapies
for congestive heart failure; included $6&nbsp;million equity investment in Targeted Genetics by
Celladon&#146;s lead investors in December&nbsp;2004;</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&#149;&nbsp;&nbsp;</TD>
    <TD>Reported that the Phase II clinical trial of tgAAVCF in patients with mild to
moderate cystic fibrosis failed to meet its primary endpoint of statistically significant
improvement in lung function, resulting in no further development of tgAAVCF.</TD>
</TR>

</TABLE>

<P align="left" style="font-size: 10pt"><B>About Targeted Genetics</B><BR>
Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and
inherited diseases. The Company has clinical product development programs, targeting AIDS
prophylaxis and inflammatory arthritis. The Company also has a promising pipeline of product
candidates focused on hyperlipidemia, congestive heart failure and Huntington&#146;s disease that are
being developed under collaboration agreements with others, and a broad platform of gene delivery
technologies for application in nucleic acid-based drug development. For more information about
Targeted Genetics, visit its website at www.targetedgenetics.com.


<P align="left" style="font-size: 10pt"><B><I>Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:</I></B><BR>
<I>This release contains forward-looking statements regarding our research programs, clinical trials,
our product development and our potential to leverage our development platforms and other
statements about our plans, objectives, intentions and expectations. In particular, the statements
regarding the Company&#146;s operating cash requirements, pipeline and potential application of research
to any future product candidates are forward-looking statements. These statements, involve current
expectations, forecasts of future events and other statements that are not historical facts.
Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of
forward-looking statements. Factors that could affect our actual results include, but are not
limited to, delay or failure in developing a product candidate, results of animal research are not
necessarily indicative of results in humans, the timing, nature and results of our research,
potential development of alternative technologies or more effective products by competitors, our
ability to obtain and maintain regulatory or institutional approvals, our ability to obtain,
maintain and protect our intellectual property related to any of our research or product
candidates, and our ability to raise capital when needed, as well as other risk factors described
in the section entitled &#147;Factors Affecting Our Operating Results, Our Business and Our Stock Price&#148;
in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2004. You should not rely unduly
on these forward-looking statements, which apply only as of the date of this release. We undertake
no duty to publicly announce or report revisions to these statements as new information becomes
available that may change our expectations</I><B><I>.</I></B>



<P align="center" style="font-size: 10pt">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="center" style="font-size: 10pt"><B><I># # #</I></B>



<P align="center" style="font-size: 10pt">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><B>TARGETED GENETICS CORPORATION</B>



<P align="center" style="font-size: 10pt"><I>(in thousands, except per share information)</I>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="80%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">Quarter ended</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000">March 31,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Statement of Operations Information:</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2005</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2004</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">(unaudited)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">(unaudited)</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Revenue from collaborative agreements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,320</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research &#038; development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,539</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,237</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General &#038; administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,885</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,750</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Restructure charges</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">219</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">195</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,643</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,182</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss from operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,643</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,862</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Investment income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">124</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interest expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(129</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(120</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(4,672</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(4,858</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss per common share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.05</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.07</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Shares used in computation of net loss
per common share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">85,628</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72,874</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">4
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><B>TARGETED GENETICS CORPORATION</B><BR>
(<I>in thousands)</I>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="80%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">March 31,</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">December 31,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Balance Sheet Information:</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2005</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2004</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" colspan="2">(unaudited)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">30,423</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">34,096</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">379</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,057</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Property and equipment, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,351</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,495</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32,257</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32,317</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">65,410</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">69,965</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,041</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,995</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Long-term obligations and other liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,273</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,208</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Shareholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45,096</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49,762</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total liabilities and shareholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">65,410</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">69,965</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">5
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>v08321v0832100.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v08321v0832100.gif
M1TE&.#EAK`#!`/<``````(````"``("`````@(``@`"`@,#`P,#<P*;*\`0$
M!`@("`P,#!$1$186%AP<'"(B(BDI*55554U-34)"0CDY.?]\@/]04-8`D\SL
M_^_6QN?GUJVID#,``&8``)D``,P````S`#,S`&8S`)DS`,PS`/\S``!F`#-F
M`&9F`)EF`,QF`/]F``"9`#.9`&:9`)F9`,R9`/^9``#,`#/,`&;,`)G,`,S,
M`/_,`&;_`)G_`,S_````,S,`,V8`,YD`,\P`,_\`,P`S,S,S,V8S,YDS,\PS
M,_\S,P!F,S-F,V9F,YEF,\QF,_]F,P"9,S.9,V:9,YF9,\R9,_^9,P#,,S/,
M,V;,,YG,,\S,,__,,S/_,V;_,YG_,\S_,___,P``9C,`9F8`9ID`9LP`9O\`
M9@`S9C,S9F8S9IDS9LPS9O\S9@!F9C-F9F9F9IEF9LQF9@"99C.99F:99IF9
M9LR99O^99@#,9C/,9IG,9LS,9O_,9@#_9C/_9IG_9LS_9O\`S,P`_P"9F9DS
MF9D`F<P`F0``F3,SF68`F<PSF?\`F0!FF3-FF68SF9EFF<QFF?\SF3.9F6:9
MF9F9F<R9F?^9F0#,F3/,F6;,9IG,F<S,F?_,F0#_F3/_F6;,F9G_F<S_F?__
MF0``S#,`F68`S)D`S,P`S``SF3,SS&8SS)DSS,PSS/\SS`!FS#-FS&9FF9EF
MS,QFS/]FF0"9S#.9S&:9S)F9S,R9S/^9S`#,S#/,S&;,S)G,S,S,S/_,S`#_
MS#/_S&;_F9G_S,S_S/__S#,`S&8`_YD`_P`SS#,S_V8S_YDS_\PS__\S_P!F
M_S-F_V9FS)EF_\QF__]FS`"9_S.9_V:9_YF9_\R9__^9_P#,_S/,_V;,_YG,
M_\S,___,_S/__V;_S)G__\S___]F9F;_9O__9F9F__]F_V;__Z4`(5]?7W=W
M=X:&AI:6ELO+R[*RLM?7U]W=W>/CX^KJZO'Q\?CX^/_[\*"@I("`@/\```#_
M`/__````__\`_P#______RP`````K`#!```(_@#_"1Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LF5#>+MBRIQ)LZ;-
MFSASZMS)LZ?/GS,1>(0$M*C1HTB3)D40QV,DEU"A/NTX-:K5E)"<7MUZ,BM5
MKF!'>N58M>&\>//2JITG-*Q;@F,WEF6(8(V!NW@-K'G+]U]<C7,7[C(`"9+>
M.(7W&J1G^.]`>'DA=8J7$(%A`Y'@T2LH+T[>NYOA?M8[CV"]RWEW%:07>5=I
MB(XQ!E9(KYY`2&M4_Y-WD%X<NPGUKAD^/'1!7</O#M=-,!)QXL9O/R?^>N"N
MZ;D-XIY>O6'LB[,;_OYF?K"N7G@([P[$35[@=0.\_^V*[3P^PM>&-]>++C_[
M0/Y^K?$:<DT]])U%X3$TGD+.7==)>@8,U(E_<*W1UC_['>0<>A@J9)A]!3DH
MD&T'X4:9="=ZI]5$"R:T1E8&%&C079'4.%QW`@WG7FGUX/B/<XC%T5Y!'R+T
M'B2((63B0`T:N*)$+1YTG6I+SFB77@;P<I".`0[G&)"&#2D:B`0="4EX5?Y(
M(4,'5I3@0E$:Y!Q>:\QV%ULOIB?@/YWLXMR#!=4G$(!C&ND?H0&FB!N'*G[%
MXIH$L29D3,#-&*&:8EX'26@3`MK<&BG^@VB14JY)8H6OO8=HB4]&%&>9_A3B
M=N%`=]DV3Z7:V5687H$Y5]BO8@9(IG6Z_NKI>B\F9B%LK3[$6!S'-F<`HX-%
M.P]A\86)4">_$38D8TC&(:X!8IX6QZP$Z1+DN(X5)FX<F474)D5O*E3/O0C=
M>ZJ^!O&+(;[YTK/JJ8,2;!K`BQ&<84'[3C3O1/7V)3&;S4YLL4,/2Q3QQ1RO
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MUV__NP9\;]'[T<?_MD;T")X`!TA`M<C#8/L+WVVD]Z/:B81_XF,=U!P8$@@N
MT'^,ZP@"OV9!OS"P?2$Z4XU&2,(2FO"$*$PA"7>QP=0IT(,8O-Q0$/.Y&MKP
MAIL3E]H>TD&?M<YK_AZ)!Y)P2,0B=NZ%!^GA!T$"C_LY\8G8F]H+?3C!'X*$
M+;S(HA:WR,4N>O&+8.0%`O`F$27&D'84_(@9)4BV-*IQBDMT8T?6*!<@IL1/
M*LRC'D>H)2DZC8U]6TD].K''0J9PAR[\8QVMN!)#.K*$X%,D8.RH$GH\\I&K
M2F35SGB\EL0#$VB+R3TRJ4FN+;**<B0:'#DYO52J4I(9$1H(7<FG50+2=!*#
M1SQVR<M>]A(>+4P@+&5#2;?@48^8>.,PP5-,MR!@CZ2D"!TGR<B^'!.%AXOD
M)F^I.XOQ`B?9U*8IJ8E*6OIQFZ=LHSDQ,LU8-G.=9;1E.@,)3V&BDYSJ_JRG
M-.6)3WKJ<R+M)&8U_UE*L7&3?'SID<`6RM"&+G0>T>0A/]TY4*Y\$A,8S:A&
M-ZK12"`R(@%E9D6M0H]=W.,>'$UI2N]!1H!.5*#EO`HO3DK3FMKTIC;%1!_M
M.4Z*QA0J)07E.X9*U*(:]:A%U>DY>PK3?%IE/PZ-JE2ENE2#SA.7!(WG,A'T
MSJPN)*1<':E7%0)6-W7U)/5`P`%".9./,J2L]#IK2>+!5IJ\8Z<NW:I9Q4J2
MDM:5)@>(:$+@"C&YAN2;[_AK3-[14I"^5*0_[6L!)_L[C1!68X8=J_L>&];(
M:O9Y>HTK7S^[V=`6=K0<.8LO5\O:UKHV'O!`_N);.;M7SW*$'O#0F6YC=H#0
MB=.J_<1J2-BRV^*ZS+>_;1LK&P@2>JC5N,9M;%65>U#Y?80>K\VN=EGK5JW1
M5K2V)2U!+JNRS(J7O.;MI'C)^MW3AM=L\HBO?.=+W_K:][[R50EZ42M#BCAW
ML4@-L(`'G%C9)E=QR_5;/1*K6)H(=H[MQ2Q_%;+6!LLDF+8SK83?NY!X'.##
M(`ZQB$=,XA(C`,,9OJ=/G;K>)$:XO!,F[7XYC,86@U;%3?6G16JCKQ[[^%X/
MMLJ,62Q<BSQ3I1N-Q`$Z-F0=.[DB"$!R1N\1SK<TN<A/KHA)58I2Y$[LRMVD
ML4/JL0LN>_G++TYO_BLW,M6L@1FA8O[LFZT;9\W.^7]U'NN=,YAGK^ZYOT2V
ML832'.,U"[JT.(9LH`_]YQHO6LM*`4NCU?OHB5SSDC62W$HF;>@L4^32F,[T
M5CC-W#X;*=38O`JI99F1D*'-P,I,=&<KW>)5J]G.A*[S+%UIZT(C1(S0A2Z*
M(:QA&)O:.JA.-DIZ?6P,)3O9FB:VK&M+:\$\&]71?N6TP5MMTUT[U%76-E,5
M[6EG4?;<`NSN@2N7X$.[N-BWWG4JF=UMAJ`%W?A.=Y`;0N]R_XR&1@PX$2,Q
M[()2]ZIAMD@](@%P@3O<<XB!]8W'/6M_0\0W4,RX$S=EV5S7N],6@<>W_D?>
MB8+/%MZ^EK<<^XUE=]<2Y;IV.:(I3FV+KY?E";_M$!_.\QR>#N=P]@ADUD?T
MHA=.XB_?MGL_;FFC.[WH'-\GS)FN\D!I_.K:<QW0Z3S<?'M]+>STN,T=+?.M
MXUGF2:<YM\?>$I,S3-S`73';!6F8C!M@WX,5>\MS#A9X,(\['9_ZW$MMY?.I
M#U=A%_S>@_Z6[3#OS'E5^H:9SA*_]@3RD5?[T@>O9[WS_?.,]CSC%R]HLVNG
M$ZA/O>I7S_K6N_[UL(^][&=/^TY$7?.39PA4I\K[WOO^]\`/OO`9ZG885A?M
M'*$BY9'O,`8RO_G+'4A:8Q)NYBN?\_*1VXLZ_A'-VMP6@0A$NDBN3WI#O2@F
MN*'/9]:`5X$,'5#7"<QIUN];UHP&"1JJ$T+DX1PDU,G+R>-_1,$LT;<<<$$H
MFC)"D$!&]8`E[K$&^C,A(A0)"[@:(L0KD7`I(0(I`@$XDL$>!A$/=H%^'(A@
MQV<0[U$01C,E"]&`P_$@(F(0$X)Y!*$>"<&"N<(<L1&#A(=[QD8V^B<?\I`6
M0XB":Z`+:7%F#4@8:R`/=1&!N7$6;J47P82#D6(7*%87YZ=N\'."@0*!`O$;
M=@$J1B@<W]&`1/$B?@>%Q*$_-;@&5<B!MY(Q$T(<%:AXH+<M>>(7%,@E&RA"
MNI`OA/$/>H$;4"A"]-%&A3<HAVL@(W3!+</!A<:'<`GA=TTH*O]P*XJQ@=&&
MAO]@B6`H@VM`@[0"AXLX)$N8(L'2'8N"AZ.',B,X#_)0APC$@OK"@(/()R^8
M1,MB&P$4'*9H*&(R(7&P&?&0/XLQ+1V8)G&78PS!&-BQ@^<3A%<H([LH)],H
M.7JQ*A,2++BA'"]B,-=Q)<,A-.27APKA)X41+QK".8%A&01W&Y)A$/-`@9I#
M+O=1&-ED26?20O-Q)H?#%O88"=G6A93X?!IQCJ^(D`GI?`SIBESWD!NAD%<S
B?!9YD1B9D1JID9-H62/WD2`9DB)9=1)9DB9YDF`1$```.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
